If AI is collapsing the cost of healthcare — are we on the brink of a historic breakthrough… or another bubble?

This week on Leading Beyond the Lab, we sit down with @Edward Kliphuis, Partner at @Sofinnova Partners, one of Europe’s leading life-sciences venture capital firms.

With over 20 years of experience spanning venture capital, digital health, tech-bio investing, and global life-sciences strategy, Edward has been at the forefront of investing where biology, computation, and healthcare collide.

In this episode, Edward covers:

- What’s genuinely different about AI in drug discovery and digital medicine today, and how collapsing healthcare costs could unlock a $10 trillion opportunity by reshaping long-term global supply–demand dynamics.

- Edward explains how @Excelsior, backed by Sofinnova Partners, @Khosla Ventures and @Deerfield Management, and led by @Mike Foley, is using an AI-driven, modular chemistry platform, originating from @Marty Burke at the @University of Illinois, to create entirely new, de novo small-molecule drugs.

- Why the US pharma & tech landscape may resemble a bubble, or a once-in-a-generation inflection point

- He talks about @Latent Labs, (led by @Simon Kohl) a Sofinnova-backed company designing entirely new proteins that do not exist in nature, unlocking new therapeutic possibilities.

- Edward outlines Sofinnova’s investment in @Bioptimus and discusses @Moon Surgical, exploring how AI and robotics are improving drug discovery and augmenting clinicians in complex procedures.

- Edward reflects on the broader AI landscape, referencing an @HSBC investment banking report questioning the long-term economics underpinning large AI models such as @OpenAI, before highlighting comments from @Geoffrey Hinton on the scalability limits of current AI architectures.

From AI-driven drug discovery and robotics in surgery, to healthcare economics, venture capital philosophy, and Europe vs the US innovation gap, this is a deep, unfiltered look at where life sciences is heading next.

To listen to (or watch) the full episode, search "Leading Beyond The Lab Edward Kliphuis" on your preferred streaming platform, or click on the first link in the comments below!

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Youtube: https://www.youtube.com/@life_sciences

Website: https://arto-talent.com

Edward Kliphuis

Partner at Sofinnova Partners

LinkedIn: https://www.linkedin.com/in/ekliphuis/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Sofinnovas Partner's Investments

17:41 The US Pharma "Bubble" & AI

28:02 Investing in the Right CEO / Company

Hosted on Acast. See acast.com/privacy for more information.

From science fiction to clinical reality. What happens when cell therapy moves from promise to proof in patients who have run out of options?

This week on Leading Beyond the Lab, Lawrence Rose sat down with Amit Rakhit, Chief Medical Officer at BlueRock Therapeutics, to explore how regenerative medicine, leadership, and culture intersect at the most pivotal stages of biotech development.

A physician by training, Amit has built his career across large pharma and early stage biotech, including experience at Bristol Myers Squibb and Biogen, working on programmes ranging from rare disease to neurodegeneration. He is also a visible advocate for authenticity and inclusion within the life sciences industry.

In this episode, Amit covers:

• How BlueRock Therapeutics is translating the promise of cell therapy into real clinical trials for Parkinson’s disease, and why this moment is so significant for patients who have exhausted existing treatments (01:09)

• What it takes to balance bold scientific vision with realism, credibility, and execution when leading clinical programmes at a pivotal stage (03:29)

• The real differences between CEO and CMO roles, why leadership is not about hierarchy, and how self-awareness shapes long-term career impact (04:58)

• Why authenticity, diversity of thought, and culture consistently separate successful biotechs from those that struggle, more than metrics alone (06:37)

• Lessons from a career spanning programmes such as Plavix and Spinraza at Biogen, and what physician scientists should consider when transitioning into industry roles (12:00)

If you want to understand how science, leadership, and empathy come together to shape medicines that can truly change lives, this is an episode worth your time.

Check out the full conversation and hear directly from one of the industry’s most thoughtful clinical leaders.

Follow ARTO: https://linktr.ee/arto_talent

Amit Rakhit

LinkedIn: https://www.linkedin.com/in/amit-rakhit/

Lawrence Rose

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Introduction and background

01:09 Cell therapy and BlueRock Therapeutics’ mission

03:29 Leadership, credibility, and execution

04:58 CEO vs CMO roles in biotech

06:37 Authenticity, inclusion, and culture

09:24 What separates successful biotechs

12:00 Physician scientists transitioning into industry

18:34 Career-defining moments and resilience

22:38 The future of cell therapy and emerging modalities

24:32 AI in drug discovery and clinical development

26:26 Closing thoughts and where to connect

#LeadingBeyondTheLab #ARTOTalent #CellTherapy #BiotechLeadership #RegenerativeMedicine #LifeSciences #ClinicalDevelopment

Hosted on Acast. See acast.com/privacy for more information.

97% of our viewers don't realise they aren't followed, please double check, thank you!

What does it really take to back and build world-class biotech companies from idea to FDA approval?

This week on Leading Beyond the Lab, Lawrence Rose sat down with Jonathan Tobin, Partner at Brandon Capital, to explore what truly drives success in life-science venture capital.

With over 20 years' experience spanning biotech investment, company creation, board leadership, and early-stage venture building, Jonathan has played a key role in building and scaling biotech companies across Europe, Australia and the US.

In this episode Jonathan covers:

- How Brandon Capital was co-founded in Australia by Chris Nave and Stephen Thompson, who grew it into a globally respected life sciences VC firm spanning company creation, long-term funding, and expansion in the US and UK.

- Jonathan reflects on how Brandon Capital has helped shape the Australian biotech ecosystem over the last almost 2 decades.

- Investments like AstronauTx, AdvanCell, Myricx Bio, and the stories from the frontline, including strategic pivots, tough decisions, successful exits, and the high-conviction bets that shaped portfolio outcomes.

- Practical, investor-led advice for founders raising venture capital; covering readiness, storytelling, common mistakes, and how to stand out in competitive funding rounds.

- How CatalYm has progressed deep into the clinic, and why Brandon Capital has supported the company through multiple funding rounds.

- Jonathan’s outlook on the future of biotech, from neuroscience and radiopharmaceuticals, to overlooked white-space opportunities shaping the next innovation cycle.

Be sure to check out the full episode of Leading Beyond the Lab, and don’t forget to like, subscribe, and share with anyone building in biotech.

To listen to (or watch) the full episode, search "Leading Beyond The Lab Jonathan Tobin" on your preferred streaming platform.

Hosted on Acast. See acast.com/privacy for more information.